Barben J, Hammer J
Division of Paediatric Pulmonary, Children's Hospital St Gallen.
Swiss Med Wkly. 2003 Jan 11;133(1-2):9-15. doi: 10.4414/smw.2003.10093.
Acute bronchiolitis is the most common lower respiratory tract infection in the first year of life. Current expert opinion and scientific data suggest that pharmaceutical agents have little impact on the natural course of the disease.
Postal questionnaires were sent to all Swiss paediatricians to assess their current practice for treating acute bronchiolitis in children.
Of a total of 937 questionnaires, 541 (58%) were returned. Of the respondents, 422 (78%) treat children with acute bronchiolitis. Up to 99% of paediatricians used bronchodilators in the outpatient and inpatient management, either routinely (up to 62%) or occasionally (37%). Steroids were used by 41% of the respondents in outpatient management and by 57% in inpatient management. The paediatric respiratory physicians tended to use bronchodilators and corticosteroids less frequently than the general paediatricians.
A wide variation in the treatment of bronchiolitis was noted. Despite lack of evidence of benefit most Swiss paediatricians use pharmaceutical agents in the management of acute bronchiolitis. In particular, bronchodilators and corticosteroids were used in inpatient management in Switzerland much more frequently than recently reported for Australian paediatricians. National guidelines could be helpful in reducing the variations in the management of acute bronchiolitis in our country.
急性细支气管炎是一岁以内儿童最常见的下呼吸道感染。当前的专家意见和科学数据表明,药物对该病的自然病程影响甚微。
向所有瑞士儿科医生发送邮政问卷,以评估他们目前治疗儿童急性细支气管炎的做法。
总共937份问卷中,541份(58%)被返还。在受访者中,422人(78%)治疗急性细支气管炎患儿。高达99%的儿科医生在门诊和住院治疗中使用支气管扩张剂,要么常规使用(高达62%),要么偶尔使用(37%)。41%的受访者在门诊治疗中使用类固醇,57%在住院治疗中使用。儿科呼吸科医生使用支气管扩张剂和皮质类固醇的频率往往低于普通儿科医生。
注意到细支气管炎治疗存在很大差异。尽管缺乏获益证据,但大多数瑞士儿科医生在急性细支气管炎治疗中使用药物。特别是,瑞士住院治疗中支气管扩张剂和皮质类固醇的使用频率比最近澳大利亚儿科医生报告的要高得多。国家指南可能有助于减少我国急性细支气管炎治疗的差异。